i-base

News

Featured 29 March 2019: vol 20 no 4 – second CROI reports

Contents online PDF of this issue Subscribe by email This issue of HTB includes our second set of reports from the recent CROI 2019 conference. These include reports on pipeline compounds from three new classes – a maturation inhibitor, a …

Featured U=U: Undetectable = Untransmittable

New Q&A on U=U… Has your doctor talked to you yet?

Featured 13 March 2019: vol 20 no 3 – First reports from CROI 2019

First 12 reports from CROI 2019….

Early reports from CROI 2019: breakthroughs in HIV care

Early reports – updated daily… including UK patient who is second man cured of HIV

22 February 2019: vol 20 no 2

Remembering Dr Mags Portman, resistance reports, marijuana safety, new BHIVA guidelines…

U=U factsheet (Arabic)

An arabic translation of an i-Base factsheet about U=U. Download leaflet  (PDF) ع جات فيروس نقص ا ناعة البشريةARTليست جيدة لصحتك فحسب-بل إنها مي أيضا شركاءك. Translation thanks to activists at ITPC MENA.

21 January 2018: vol 20 no 1: Brexit and other complications…

Brexit, other complications and benefits of DTG/TDF/3TC in sub-Saharan Africa….

12 December 2018: vol 19 no 18: Final issue of 2018

Contents online PDF of this issue Subscribe by email This last slim issue of HTB this year includes final reports from recent conferences, including HIVR4P and Glasgow 2018. We also report that doravirine and the FDC with TDF and 3TC …

Modern ART for Africa…

Resources with Treatment Action Campaign on modern ART in Africa…

HTB issue 17: HIVR4P and Glasgow conferences – first reports

Integrase inhibitors and pregnancy, new approaches to PrEP, why U=U is not for breastfeeding and more…

3rd HIV Research for Prevention Conference (R4P2018)

21–25 October 2018, Madrid Introduction The Research for Prevention (R4P) conferences are held every two years to focus on vaccines, PrEP, microbicides, treatment as prevention and other biomedical prevention approaches. This year the meeting was held in Madrid and attended …

HTB issue 16: BHIVA and Ageing Conferences, PrEP guidelines

Contents online PDF of this issue Subscribe by email This issue of HTB includes diverse news and reports that cover a surprising and disturbingly wide ground. Even though this was expected to be a quiet month, there is a lot …

PrEP in Scotland – new guide (July 2018)

PrEP in Scotland is a the second edition of a booklet produced by the PrEP coordination group in Scotland. PrEP In Scotland (2nd edition) July 2018 – download/view PDF file For free print copies of this 16-page A5 booklet, please contact: …

HTB issue 15: UK diagnoses, U=U resources, generic PrEP

Latest HTB online. Generic PrEP in England, UK surveillance data, AIDS 2018 reports and more…

U=U resources for UK clinics

i-Base have produced new resources to help raise the profile of U=U in UK clinics. A3 colour posters A6 double-sided post cards U=U factsheet leaflets: Q&A format to explain U=U in more detail. This leaflet is formatted to print in …

HTB: issue 14 online: AIDS 2018 – next reports

Further reports from AIDS 2018: global health, HPV, PrEP, cure, diagnostics + more…

HTB: issue 13 online: AIDS 2018 – first reports

PARTNER2, GEMINI, dolutegravir and pregnancy, DRV/r once-daily, cure research and more

Fit for Purpose: treatment optimisation reports (2012 – 2018)

– Fit for Purpose is an i-Base publication about HIV treatment strategies for low and middle-income countries. The latest edition was launched at the AIDS 2018 conference in Amsterdam in July 2018. Read July 2018 edition online. This report is …

Adult and paediatric optimised ART trial tracker

Trial Tracker is a new i-Base resource publishes routinely updated tables on the web. This is freely available via i-Base’s Google Docs. Op ART trial tracker i-Base’s Op ART trial tracker follows research on optimised antiretroviral treatment for low- and …

AIDS 2018: early i-Base reports from Amsterdam

23 – 27 July 2018, Amsterdam Early reports i-Base reports, including from the HIV paediatric workshop held before AIDS 2018, will be added to the list of articles below. WHO recommends dolutegravir widely but women’s access will depend on contraception …

Post navigation